VSTM News - Candlesense

Verastem Oncology to Present at Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that i...

Conference

about 4 hours ago

Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics’ Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK-pathway-driven cancers, today announced positi...

Are there any upcoming data readouts, additional trial cohorts, or combination therapy studies that could further de‑risk the commercial potential of GFH375? What are the potential pricing strategies for GFH375 in China, and how might they differ from pricing in other regions? Will the positive data trigger any changes in the company’s guidance or financial forecasts?

Clinical trials

14 days ago

Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced busine...

How does the recent press release reconcile with the company's previously disclosed 2025 revenue growth expectations and analyst estimates? Is there any guidance on partnership or co‑marketing agreements for the new drug that could affect future revenue streams? What is the expected impact on the stock’s short‑term price volatility and implied volatility for options after the news?

Earnings

20 days ago